Navigation Links
EU Study Finds UK Health Product Benefit Metric Flawed
Date:2/1/2013

Washington, D.C. (PRWEB) January 31, 2013

RegLink News, in its monitoring of developments at regulatory and health technology assessment (HTA) agencies around the world, is accustomed to reporting on decisions as to coverage or not of new drugs and medical devices. This week’s HTA news has significance well beyond a particular product: A study funded by the European Commission has just concluded that the formula used by the UK’s healthcare cost containment watchdog, the National Institute for Health and Clinical Excellence (NICE), doesn’t work – and in so doing has sparked off a debate on the subject of determining patient access to new therapies.

The study, conducted by the European Consortium on Healthcare Outcomes and Cost-Benefit research (ECHOUTCOME), examined the scientific validity NICE’s formula – Quality Adjusted Life Years (QALY) – and found that it doesn’t reflect real world needs and preferences of patients.

QALY weighs the number of life years and the improvement to quality of life, and is the basis for reimbursement decisions delivered by many health technology assessment (HTA) agencies around the world, including – in addition to NICE – those in Canada and Australia. The metric has, however, been rejected by some HTA bodies, including notably Germany’s IQWiG.

The ECHOUTCOME group’s report on NICE’s methodology comes right out and says that the use of QALY “produce[s] hugely inconsistent, wrong results, on which important [reimbursement] decisions are based.” The report concludes that all four of the assumptions which allegedly support the use of QALY are invalid: (1) that time and quality of life can be measured in consistent intervals; (2) that life years and quality of life are linked; (3) that people are neutral about risk; and (4) that willingness to sacrifice life years is co
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Positive Clinical Study Results for BSPs HyperQ Technology
2. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
5. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. Singapore scientists lead human embryonic stem cell study
9. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
10. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
11. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 18, 2014 ... nation’s leading specialty pharmacies, has an expanded team ... clinical pharmacy consultants for prescriber offices in their ... , “We have a variety of Regional ... example, those specializing in hepatitis C help prescribers ...
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 Reports from ... the United States suffer from one or more chronic ... or cancer. Medication can address some of these diseases, ... activities that many sufferers face. While implanted nerve stimulation ... stimulate the whole nerve, which can induce side effects. ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 In contrast ... of LEDs with various colors, Valoya uses proprietary LED ... This offers best possible uniformity which is critical in ... and high spectral accuracy throughout its lifetime which is ... LED tubes. , "The investment cost was clearly ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
... CITY, Panama, May 21, 2012 International scientific ... to discuss the potential use of Oxitec,s genetically modified ... Fever in Panama. The independent forum was co-organised ... Institute for Health Studies and the University of Panama. This ...
...  Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that Dr. ... will be presenting at the Seventh Annual Neurotech ... http://photos.prnewswire.com/prnh/20111214/NY22484LOGO ) The title of ... Attractive Targets for Active and Passive Immunotherapy." His ...
... May 16, 2012  Sigma-Aldrich announced today that it has ... will mature on May 10, 2017.  The new facility ... scheduled to mature on December 11, 2012.  The $600 ... paper program and be used for general corporate purposes. ...
Cached Biology Technology:Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 2Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 3Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 2Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 3
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that ... and at least seven more will participate in the upcoming ... Hotel in Washington D.C. , Dec. 2-4. ... support from the regulatory agencies in the United ... our effort to help advance the use of metrics in ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... part of their ongoing research on the physiologic factors that ... have identified a cell cycle transcriptional co-regulator TRIP-Br2 ... storage. This finding has the potential to lead to ... ahead of print by Nature Medicine . Transcriptional ...
... Many of the nation,s foremost authorities on cyber security ... Cyber Sciences Laboratory workshop. The event will feature 10 plenary ... Threat to National Security and What to do About it." ... talks and 20 research posters. Researchers from nine Department of ...
... Barbara, Calif.) While legions of medical researchers have ... and how mutations may affect human health, a group ... the metabolism of cells and their surrounding tissue, to ... approach, which includes computer modeling, can be applied to ...
Cached Biology News:Joslin researchers identify important factor in fat storage and energy metabolism 2January 2013 story tips from Oak Ridge National Laboratory 2UCSB researchers perform pioneering research on Type 2 diabetes 2UCSB researchers perform pioneering research on Type 2 diabetes 3